By high-throughput screens of somatic mutations of genes in cancer genomes, hundreds of cancer genes are being rapidly identified, providing us abundant information for systematically deciphering the genetic changes underlying cancer mechanism. However, the functional collaboration of mutated genes is often neglected in current studies. Here, using four genome-wide somatic mutation data sets and pathways defined in various databases, we showed that gene pairs significantly comutated in cancer samples tend to distribute between pathways rather than within pathways. At the basic functional level of motifs in the human proteinprotein interaction network, we also found that comutated gene pairs were overrepresented between motifs but extremely depleted within motifs. Specifically, we showed that based on Gene Ontology that describes gene functions at various specific levels, we could tackle the pathway definition problem to some degree and study the functional collaboration of gene mutations in cancer genomes more efficiently. Then, by defining pairs of pathways frequently linked by comutated gene pairs as the between-pathway models, we showed they are also likely to be codisrupted by mutations of the interpathway hubs of the coupled pathways, suggesting new hints for understanding the heterogeneous mechanisms of cancers. Finally, we showed some between-pathway models consisting of important pathways such as cell cycle checkpoint and cell proliferation were codisrupted in most cancer samples under this study, suggesting that their codisruptions might be functionally essential in inducing these cancers. All together, our results would provide a channel to detangle the complex collaboration of the molecular processes underlying cancer mechanism. Mol Cancer Ther; 9(8);
Introduction
Current cancer genome projects (1) have generated a large amount of somatic mutation data in cancer, endowing us with a promising landscape of the systematic variation of the cancer genome (2) (3) (4) (5) (6) . Based on highthroughput somatic mutation data, the identification of genes that may carry driver mutations is most often addressed, shedding lights on the studies of cancer mechanism (7, 8) . Despite its great contribution to the field, focusing on the mutation frequency of individual genes is insufficient to exploit the full potential of mutation profiles because the combinatorial effects of gene mutations may play key roles in cancer initiation and progression. Uren et al. (9) revealed significantly co-occurring and mutually exclusive mutations between cancer genes in mice with either p53 or p19ARF deficiency. By studying 238 known oncogenes across 1,000 human tumor samples, Thomas et al. (10) also observed an unexpectedly high number of co-occurring mutations among 17 mutated oncogenes. Recently, Ding et al. (6) identified co-occurring and mutually exclusive mutations among 623 genes in a mutational screens on 188 samples of human lung adenocarcinomas. These intriguing results indicate that collaborations between genes may exist during carcinogenesis.
On the other hand, it is becoming increasingly clear that pathways rather than individual genes govern the course of carcinogenesis (11) . Mutations in many different genes of a single pathway can thereby cause cancer susceptibility. Accordingly, most current cancer genome studies (3, 4, 6, 12, 13) have developed methods to investigate whether genes within some biological pathways are mutated more often than expected by random chance, assuming that alterations of such "core pathways" are essential to the course of carcinogenesis. So a natural question raised is how the mutated genes distribute among cancer-related pathways. One of the most prevailed hypotheses (12, 14, 15) is that, compared with a single mutation, mutations of two genes participating in the same pathway rarely confer a significant growth advantage on tumor cells. By contrast, mutations of genes that participate in different biological pathways may be collaborative in conferring growth advantage on the tumor cells. Previous studies have partially supported this hypothesis. Using somatic mutation data from the COSMIC database (16) , based on six pathways defined by themselves, Yeang et al. (15) showed that mutations of genes in coordinated pathways tend to co-occur in cancer samples, whereas genes annotated in the same pathways rarely mutate together in the same cancer sample. Lin et al. (14) found mutually exclusive mutations among genes in sequence similarity clusters. A recent publication of the Cancer Genome Atlas (12) reported a tendency toward mutual exclusivity of genetic alterations within the "core" pathways they defined.
However, the definitions of pathways adopted in current studies are often inconsistent, which could introduce great uncertainty to functional analyses of comutated genes. For example, in the study by Yeang et al. (15) , two genes (K-Ras and PTEN) were included in the RAS and insulin-like growth factor-AKT pathways, respectively, which validated the between-pathway model hypothesis. In the Cancer Genome Atlas publication (12), however, these two genes were assigned to the receptor tyrosine kinase/RAS/PI(3)K signaling pathway, which integrates the RAS and insulin-like growth factor-AKT pathway as one pathway, and their comutation would be judged as within-pathway. In general, in different pathway databases such as Kyoto Encyclopedia of Genes and Genomes (KEGG; ref. 17) and BioCarta (18), the specificities of the documented pathways vary greatly, and especially, the same-named pathways are often inconsistent with different components and unclear boundaries (19) . Generally speaking, KEGG inclines to define general pathways, whereas BioCarta tends to define specific pathways. For example, the intracellular signaling Wnt pathway can be divided into three branches: (a) the β-catenin pathway (canonical Wnt pathway), (b) the planar cell polarity pathway, and (c) the Wnt/Ca2+ pathway. KEGG integrates all of them together as Wnt signaling pathway, whereas BioCarta defines the Wnt/ β-catenin pathway as the Wnt pathway. In contrast, Gene Ontology (GO; ref. 20 ) defines pathways at various specific levels in a hierarchical way, including general pathways similar to those in KEGG as well as pathways that can be as specific as what is defined in BioCarta.
In this article, based on a meta-data set integrated from four data sets of genome-wide somatic mutation screens of cancer genomes (3, 4, 13) , we investigated the functional patterns of comutated genes from multiple perspectives and focused on analyzing the influence of various pathway definitions on the conclusions (Fig. 1) . First, using pathways defined in various data sources (KEGG, BioCarta, and GO), we searched for pathway pairs between which genes are comutated more often than expected by random chance (between-pathway models), and individual pathways within which comutated gene pairs are overrepresented (within-pathway models). Our results showed that comutated gene pairs tend to distribute between pathways rather than within pathways, but the results may be affected by the pathway definitions. Then, at the level of motifs that are basic functional units in the organization of the protein-protein interaction (PPI) network based on the data from the Human Protein Reference Database (21), we found the comutated gene pairs are also extremely depleted within motifs but overrepresented between motifs. Together, these results suggest that the codisruptions of the coupled pathways in the between-pathway models by comutated genes between the pathways might be functionally essential in inducing cancer. In addition, we showed that compared with the other two databases analyzed in this study, GO provides a more flexible and powerful tool for finding cooperative pathways because it describes biological functions at various specific levels. Furthermore, we sought proteins with dense PPI connections to both pathways in a between-pathway model based on GO, termed as interpathway hubs of the model, and found that they are likely to be cancer genes whose mutations Figure 1 . The flowchart of our analysis procedure. The META data were comprised of mutation profiles for glioblastoma, breast, colorectal, and pancreatic cancers. First, we defined candidate comutated gene pairs by using Fisher's exact test. Then, by stringent FDR control, we searched between-pathway models and within-pathway models based on pathways predefined in various data sources (KEGG, BioCarta, and GO). Last, based on PPI data, we identified the interpathway hubs for between-pathway models to reveal their roles in disrupting the models.
could disrupt both pathways of the model. Finally, for some between-pathway models consisting of important pathways such as cell cycle checkpoint, cell proliferation, and regulation of cyclin-dependent protein kinase, we showed that both pathways in each model were codisrupted in most cancer samples under this study, indicating that the codisruptions of these models might be functionally essential in inducing cancer.
Materials and Methods

Pathways and PPI data
The pathway data were downloaded from KEGG (17) and BioCarta (22). The annotation data of GO (20) 
Meta-data set of mutation profiles
Because the sample size for each cancer is small, we integrated somatic mutation profiles for four cancers to identify comutated genes and pathways (see Discussion). We constructed a meta-data set of 556 genes altered in at least 2 of the 67 cancer genomes sequenced in the discovery screen stage of the original projects for four cancers (glioblastoma, breast, colorectal, and pancreatic cancer; refs. 3, 4, 13; see Supplementary Table S1 ). The genetic alteration data in the meta-data set included missense and nonsense single-base substitutions; insertions and deletions of DNA segments; and changes in splice sites and untranslated regions, homozygous deletions, and focal amplifications (see Supplementary Table S2 ). Here, we did not analyze samples sequenced in the validation stage of the original projects because only a few genes were sequenced for all the cancer types in this stage.
All glioblastoma samples were recorded as "glioblastoma multiforme (grade IV)," except for two samples recorded as "high-grade glioma" (4) . Seven of the pancreatic cancers were metastasized and 17 were at late-stage IIB or IV (3). The colorectal cancer samples were all at the late stage and most of the breast cancer samples represented invasive types (see Supplementary  Table S3 and some related discussion in the Discussion section; ref. 13 ).
Identification of between-and within-pathway models
First, the probability (P value) of observing a pair of genes mutated together in no less than n samples by random chance was calculated by using the two-sided Fisher's exact test. The gene pairs with P values exceeding a threshold were defined as candidate comutated gene pairs. At this step, we did not use false discovery rate (FDR) control because the statistical powers of most multiple test adjustment methods (including the BenjaminiHochberg FDR control procedure; ref. 24 ) may decrease when the number of tests increases (25) . In the following step of pathway analysis, we identified comutated pathway pairs by FDR control. In the part of GO-based pathway analysis, we verified by randomized experiments that the pathway analysis results would be robust to a certain level of false positives in the candidate comutated gene pairs (see Results).
In the step of pathway analysis, for two pathways defined in a given database, we calculated the probability (P value) of observing no less than m pairs of comutated genes between their nonoverlapped genes by random chance by the hypergeometric distribution model (26) . The hypergeometric distribution is a discrete probability distribution that describes the number of observing m interesting objects (here, comutated gene pairs) in M objects (here, all pairs of mutated genes between two given pathways), which are randomly sampled without replacement from N objects (here, all pairs of mutated genes between all pathway pairs in a database), which includes n interesting objects. By the hypergeometric distribution model (26) , the probability of observing m comutated gene pairs from a total of M gene pairs between two pathways by chance was calculated as:
Then, the probability (P value) of observing no less than m pairs of comutated genes between the two pathways by random chance was calculated by:
A small P value is evidence against the null hypothesis (H 0 ) that the ratio of comutated gene pairs between the two pathways to all possible gene pairs between the two pathways is the same as expected by random chance. The raw P values were adjusted by the Benjamini-Hochberg FDR control procedure (24) . To find within-pathway models, we applied the same approach to examine whether an individual pathway is overrepresented with comutated gene pairs.
Investigation of comutated gene pairs between and within motifs
By using the iGraph package (27), we extracted motifs with k-nodes (k = 3, 4, 5) appearing recurrently in the human PPI network from the Human Protein Reference Database. The probability (P e ) of observing a comutated gene pair encoding two interacting proteins in the PPI network by random chance was calculated as the number of pairs of comutated genes with protein interaction links divided by the number of all interactions in the PPI network. Then, for a k-node motif, we estimated the probability of observing i within-motif comutated gene pairs by random chance as follows:
in which i is the number of comutated gene pairs within the motif and n is the number of all possible gene pairs within the motif. If K was the number of k-node motifs identified from the PPI network, then the expected number of k-node motifs with i pairs of within-motif comutated genes was calculated as: E (e = i) = KP. The expected number of k-node motif pairs with i between-motif comutated gene pairs was calculated in the same way. For clarity, we only considered motif pairs without overlapping nodes.
Identification of interpathway hubs for betweenpathway models
We generated a network of comutated pathways by linking the comutated pathways in between-pathway models with edges. Then, in the PPI subnetwork comprising of the proteins in the comutated pathway network, by Fisher's exact test, we sought proteins with dense PPI connections to both pathways in a betweenpathway model, termed as the interpathway hubs of the model. In our work, we set four significant levels to define interpathway hubs.
Results
Functional relations of comutated gene pairs
By the two-sided Fisher's exact test, we identified 421 pairs of genes with correlated mutations (P < 0.05). We focused on studying the 417 pairs of genes with positively correlated mutations, called (candidate) comutated gene pairs, which involved a total of 336 genes in the Meta mutation profile (see Supplementary Table S4 ). We did not consider the four pairs of negatively correlated genes whose mutations might be mutually exclusive (12) .
Based on the pathways defined in the BioCarta and KEGG databases, neither between-pathway models nor within-pathway models were identified with a FDR of <10% partially because there were only 10 and 50 comutated gene pairs that were annotated in these two databases, respectively. However, we observed 10 and 47 pairs of comutated genes that were distributed between pathways defined in the KEGG and BioCarta databases, respectively. In contrast, only one pair of comutated genes was within a pathway in the BioCarta database. In the KEGG database, although we observed 25 comutated gene pairs within some large pathways named with cancer types, these large pathways are actually cohorts of some classic signaling pathways collaboratively contributing to cancers. For example, the "Pancreatic cancer" pathway is composed of the K-Ras/Rho pathway, Jak-STAT pathway, P53 signaling pathway, cell cycle pathway and transforming growth factor-β (TGF-β) pathway, which work together during the pancreatic cancer initiation and progression. As shown in Fig. 2 , some comutated gene pairs were distributed between these collaborative subpathways: K-Ras in the K-Ras/Rho pathway was comutated with SMAD4 in the TGF-β pathway; P16 in the cell cycle pathway was comutated with SAMD4 in the TGF-β pathway; and K-Ras in the K-Ras/Rho pathway was comutated with P16 gene in the cell cycle pathway (Fig. 2, black dashed lines) . Therefore, the tendency of the comutated gene pairs "within" the pancreatic cancer pathway may actually reflect the collaboration between some specific signaling pathways.
Many more (285) pairs of comutated genes were annotated in BP of GO than in KEGG and BioCarta databases, which could provide higher power to identify significant models. With a FDR level of 10%, we found no within-pathway models but 281 significant between-pathway models covering 170 distinct BP terms after removing the redundant child terms whose parent terms were comutated with the same terms (Supplementary Table S5 ; Fig. 3A) . To further show that the results obtained under the FDR control process would not be introduced in random data, we generated 1,000 sets of random gene pairs from the meta-data set, with each set consisting of 285 gene pairs, which was the number of comutated gene pairs annotated in GO. With the same FDR control level of 10%, the pathway analysis process was repeated in each randomized data set. The result showed that in only 7.9% (less than 10%) of the random experiments, we could identify between-and/or withinpathway models. Averagely, the number of the betweenpathway models observed in a random experiment was only 0.5, which was much less than the number (281) of the between-pathway models observed in the actual data set. In other words, the number of the between-pathway models derived from the actual data set was significantly more than expected by random chance (P < 0.001).
Based on GO, which describes gene functions at various specific levels in a hierarchical way, we could find cooperative pathways more efficiently. For example, GO describes "cell cycle" as well as its specific subpathways such as "mitotic cell cycle" and "G 1 -S transition of mitotic cell cycle" (Fig. 4A) . Based on GO, we detected that pathway "G 1 -S transition of mitotic cell cycle" was significantly comutated with "sensory perception of mechanical stimulus." However, this comutation relationship could not be found based on KEGG because no subpathways of cell cycle are described in KEGG. As shown in Fig. 4B , genes in GO term G 1 -S transition of mitotic cell cycle can be mapped to a part of the KEGG pathway cell cycle, indicating that alternations of this part of the cell cycle pathway might play key roles in providing growth advantages to cancer cell.
Finally, without using predefined pathways, we investigated the distribution of comutated gene pairs within and between 3-or 4-node motifs appearing recurrently in the human PPI network, considering the motifs as some basic functional units of the network (28). We found , see Supplementary Table S6-1). In contrast, comutated gene pairs between 3-or 4-node motifs were significantly more than expected by random chance (P < 1 × 10
; see Supplementary Table  S6 -2). We also searched 5-node motifs and found 5,589 such motifs that were highly overlapped. These motifs included a total of 616 genes that were tightly connected together to form a subnetwork. The genes within the subnetwork had significantly more interactions among themselves than with the other genes in the PPI network (P < 2.2 × 10 −16 , Fisher's exact Test), suggesting that they may participate in the same or similar functional module (29) . There were 14 mutated genes in this subnetwork among which no comutated gene pairs were detected, which could be explained by the within-pathway model when considering that this subnetwork might be a functional module. Similar results were observed for motifs with six or more nodes.
The interpathway hubs for between-pathway models
As shown in the above results, GO provides a more overall description of pathways for studying functional collaboration of gene mutations in cancer genomes. Therefore, in the following text, we focused on analyzing the models based on GO. Here, based on the comutated pathway pairs identified from GO, we constructed a network in which nodes represent pathways and edges represent the nonrandom comutations between the pathways (Fig. 3A) . In the PPI subnetwork comprising of the proteins in the comutated pathway network, by Fisher's exact test (P < 0.01), we identified a total of 380 interpathway hubs that were significantly overrepresented with cancer genes collected in cancer gene census database (P = 2.07 × 10
; ref. 30) . Then, we randomly sampled 1,000 gene sets with the same degree distribution of the interpathway hubs and found that the fraction of cancer genes in each random gene set was less than that in the interpathway hubs (P < 0.001). Thus, the high prevalence of cancer genes among the interpathway hubs was not induced by their higher degrees in the PPI network. When we set different thresholds to define hubs (P < 0.05, 1 × 10 ), consistent results were observed (see Table 1 ).
Examples of between-pathway models
The two pathways codisrupted by comutations of genes between the two pathways may collaboratively contribute to carcinogenesis. Considering that the interpathway hubs of a between-pathway model are likely to be cancer genes, we assumed that their mutations may be an alternative way of disrupting both pathways of the betweenpathway model. Based on this assumption, we analyzed four significant between-pathway models ( Table 2) whose alterations had the top ranked coverage of the cancer samples in the meta-data set. The disruption of each of these four models, by either the comutation of genes between the two pathways or the mutation of the interpathway hubs of the model, was observed in 61 (91%), 60 (90%), 58 (87%), and 56 (84%) of the 67 samples in the meta-data set, respectively. The first model was "interphase" coupled with "regulation of cyclin-dependent protein kinase activity" whose codisruption could be observed in all pancreatic and breast cancer samples. The second model, namely "cell cycle checkpoint" coupled with regulation of cyclin-dependent protein kinase activity, was also codisrupted in all the pancreatic cancer samples. Both the third and fourth models included the cancer-associated pathway "negative regulation of cell proliferation" (31) whose codisruption with "negative regulation of transcription" (the third model) and "growth" pathways (the fourth model) was observed in 58 (87%) and 56 (84%) of all samples, respectively.
Then, we analyzed the fourth between-pathway model in detail. First, in some cancer samples, the interruption of the two pathways in this model could be introduced by different pairs of comutated genes between the pathways. As shown in Fig. 3B , the tumor suppressor genes DLEC1 mutated in four samples, whereas it mutated together with SMAD4 in three samples. Indeed, Yuan et al. (32) found that the comutation of DLEC1 and SMAD4 in human breast cancer may contribute to the metastasis process. APC and BMP6 were mutated in nine and two samples, respectively, whereas they were mutated together in two samples. Holcombe et al. (33) reported that these two genes may play synergistic roles in the carcinogenesis of colon. Other significant comutated gene pairs in this case include PTEN and RB1. Dysfunction of RB1 in combination with loss of PTEN was detected in glioblastoma patients (34) . Second, in some other cancer samples, the two pathways of this model could be codisrupted by the mutations of interpathway hubs. For example, EP300 as an interpathway hub between the two pathways ( Fig. 3B ) may play central roles in cellular proliferation by regulating key components of cell cycle and act as a suppressor during cell growth (35) .
Although some false discoveries may exist, significant between-pathways models with relatively low coverage of the cancer samples may also play important roles in carcinogenesis. For example, the between-pathway model "muscle fiber development" coupled with "neuron differentiation" covered 17% of all the cancer samples. We found both COL4A4 and CACNA1H playing Figure 3 . The network of comutated pathways. A, the pathway network constructed by linking the comutated pathways together. The nodes denote the pathways (BP terms), and the edges denote the comutation relations between pathways. Sizes of the nodes, the numbers of gene annotated in the pathways; shades of colors, the ratio of candidate cancer genes in the pathways. A total of 373 candidate cancer genes were identified in four cancer types by large-scale sequencing of tumor samples (3, 4, 13) . The graphs were drawn by Cytoscape 2.6.0 (54). B, a core signal transduction network involving negative regulation of cell proliferation pathway and growth pathway. Nodes, genes that participate in pathways; octagon nodes, interhubs. Gray edges, the regulation relation between genes. Red dashed line, comutation relation between mutated genes. roles in muscle fiber development (36) (37) (38) were significantly comutated with gene AGRN in the neuron differentiation pathway associated with cancer (39).
Discussion and Conclusions
It has been suggested that the combinatorial effects of gene mutations might be functionally essential in carcinogenesis (6, 15, 29) . However, most previous analyses addressing this problem were biased toward mutation data of some research hot spot genes and only a few special biological pathways. What is more problematic is that the inconsistent descriptions of pathways adopted in current studies could introduce great uncertainty to the conclusions. To our best knowledge, this article is the first study providing a largely unbiased overview of the functional cooperation of comutated genes in cancer genomes based on whole genome sequencing data. First, by investigating the biological pathways defined in different databases and at different specific levels, we consistently found that comutated gene pairs tend to distribute between pathways rather than within pathways. Our results suggested that, in a rather broad range of pathway definition, the codisruptions of between-pathway models may play essential roles in carcinogenesis. Especially, our results also showed that compared with KEGG and BioCarta, GO provides a more overall description of pathways based on which we could study more efficiently the functional collaboration of gene mutations in cancers. Second, we showed that in some cancer samples, the coupled pathways in the between-pathway models could also be codisrupted by mutations of the interpathway hubs, providing new hints for understanding the heterogeneous mechanisms of cancers. Third, methodologically different from other works, we did not use the driver mutations reported in the original studies because current methods of identifying driver mutations might be rather uncertain due to the varied background mutation rates of genes (5, 13, (40) (41) (42) . Alternatively, we assumed that the nonrandom comutation of genes in cancer genomes could provide statistical evidence of the involvement of these genes in carcinogenesis. Based on this assumption, we showed that comutated pathways could be systematically identified with stringent FDR control. As shown by our analysis, because GO describes biological functions at various specific levels, it is relatively suitable for tackling the pathway definition problem. However, because GO annotations are redundant, the comutation relationship of a child term with another term may be inherited from its parent or, oppositely, the significance of the parent term is just introduced by its significant child(s). In this study, to tackle this problem, we roughly kept the comutation relationship of the parent term with another term, assuming that the significance of the child term may be inherited from its parent. To be more statistically sound and biologically meaningful, we could design algorithms to improve the selection of nonredundant comutated term pairs, perhaps by some similar approaches proposed for analyzing the enrichment of interesting genes in individual terms (43, 44) . To further solve the pathway definition problem, we might need to integrate other data sources such as PPI network and gene expression profiles to define disease-associated pathways (19, 45, 46) .
The comutation of gene pairs studied in this article is analogous to the genetic interaction of synthetic lethality in which the combination of mutations in two or more genes can lead to cell death. Numerous methods have been developed to interpret genetic interactions by using functional pathways and PPI networks (47) (48) (49) , revealing the functional compensation or redundancy of the pathways contributing to cell survival. Among these, Kelley and Ideker (47) used physical interactions of proteins to identify within-pathway and between-pathway explanations for genetic interactions and concluded that genetic interactions most often take place between pathways. The studies based on large-scale genetic interaction data have shown their values in predicting gene functions and screening drug targets. Similarly, we expect that studying the comutation patterns of genes in cancer genomes will provide a channel to detangle the complex collaboration relationship of the underlying cellular and molecular processes in cancer mechanism.
In this work, we integrated somatic mutation profiles for different cancers to study the functional cooperation of comutated genes in cancer genomes. Although cancers of different tissues exhibit considerable variation in their mutational profiles, it is known that they may all alter several essential cellular functions (hallmarks) that collectively dictate malignant growth for almost all human cancers (30, 31) . As shown in our recent work (50) , most cancer gene lists derived for different cancers are actually highly consistent at the functional level, indicating that they may separately capture partial genes participating in the same cancer-associated pathways. For the four cancers under this study, by the method proposed in ref. (50), we also found their cancer gene lists, derived from refs. (50, 51), were highly consistent in functions ( Supplementary Fig. S1 ). Thus, it should be reasonable to pool together their somatic mutation profiles to find comutated pathway pairs that tend to be shared by these cancers. We have also tried to analyze each cancer separately. However, because the sample size for each cancer might be too small to provide enough statistical power (52), we found no significant comutated pathway pairs under the FDR control level of 10%. We believe that more samples are in need for finding comutated genes and their functional cooperation specific to a cancer.
Another problem that needs to be noted is that most of the cancer samples analyzed in our study were fully progressed neoplasm and lethal, which contained all the mutations happened at earlier developmental stages of these cancers (13) . The increasing propensity of passenger mutations at later stages might affect the ratio of mutations within and between pathways. However, under the assumption that the passenger mutations are not subject to selection and randomly happen in cancer genomes (53), they could be filtered out by the following statistical process of finding nonrandom comutations. Thus, our conclusions would not be biased by the increasing propensity of passenger mutations at late stages. Obviously, based on current sequencing projects that only scan malignant cancer samples, we cannot distinguish the driver mutations and their functional cooperation for cancer initiation and progression (13, 53) . Therefore, efforts for sequencing cancers at different development stages are in need for sorting out stage-specific driver mutations and analyzing their functional cooperation. 
